Specifically, the FDA okayed the removal of a bioscan requirement for Zevalin, making it more convenient for lymphoma patients to receive treatment with the drug.
Zavoico, senior life sciences analyst at investment research firm MLV, forecasts that the bioscan removal will enable Spectrum to post record earnings in the fiscal third quarter of 2012.